

# T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/T9A629B607CEN.html>

Date: May 2018

Pages: 48

Price: US\$ 3,500.00 (Single User License)

ID: T9A629B607CEN

## Abstracts

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

### SUMMARY

According to the recently published report 'T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2018'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

The report 'T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2018' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications

Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Encephalomyelitis, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Sepsis, Skin And Soft Tissue Infections, Solid Tumor, Stem Cell Transplantation, Systemic Lupus Erythematosus and Uveitis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in  
Therapeutics Development

Atox Bio Ltd

Five Prime Therapeutics Inc

Johnson & Johnson

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles

ALPN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALPN-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize CD278 and CD28 and Antagonize PD-1 for Oncology -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development

Milestones

Featured News & Press Releases

Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease

Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vlgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

Sep 20, 2017: Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting

Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data

Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vlgDs in an Animal Model

May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections

Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Atox Bio Ltd, H1 2018  
Pipeline by Five Prime Therapeutics Inc, H1 2018  
Pipeline by Johnson & Johnson, H1 2018  
Pipeline by TheraMAB LLC, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Atox Bio Ltd

Five Prime Therapeutics Inc

Johnson & Johnson

TheraMAB LLC



## I would like to order

Product name: T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/T9A629B607CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9A629B607CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970